| Entry |
|
|---|
| Name |
FUS-DDIT3 fusion to NFKB-mediated transcription
|
|---|
| Definition |
FUS-DDIT3 == (NFKBIZ+NFKB) => CXCL8 |
|---|
| Expanded |
1649v1 == (64332+4790+5970) => 3576 |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Disease |
|
|---|
| Gene |
| 1649 | DDIT3; DNA damage inducible transcript 3 |
| 64332 | NFKBIZ; NFKB inhibitor zeta |
| 4790 | NFKB1; nuclear factor kappa B subunit 1 |
| 5970 | RELA; RELA proto-oncogene, NF-kB subunit |
| 3576 | CXCL8; C-X-C motif chemokine ligand 8 |
|
|---|
| Variant |
1649v1 (FUS-DDIT3) FUS-DDIT3 fusion
|
|---|
| Reference |
|
|---|
| Authors |
Goransson M, Andersson MK, Forni C, Stahlberg A, Andersson C, Olofsson A, Mantovani R, Aman P |
|---|
| Title |
The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Willems SM, Schrage YM, Bruijn IH, Szuhai K, Hogendoorn PC, Bovee JV |
|---|
| Title |
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
